- Published at
- by manilatimes.net
neutral
neutral
News for CytoDyn Inc. (CYDY)
- Published at
- by manilatimes.net
positivepositive- Published at
- by gurufocus.com
mixedmixedAIM's Clinical Strategy Under Incumbent Board Has Totally Failed
Incumbent Board's Claims of Progress Are Not Credible or Supported by DataAIM Maintains Relationship with CRO Co-Founded by a Convicted Felon Who Deceived Inves- Published at
- by gurufocus.com
positivepositiveCytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
VANCOUVER, Washington, Nov. 25, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. ( CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a C- Published at
- by manilatimes.net
neutralneutral- Published at
- by globenewswire.com
positivepositiveCytoDyn Announces Abstract that Highlights Leronlimab’s Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
Abstract to be presented at the 5th annual HIV Research for Prevention Conference Study results highlight potential for treatment VANCOUVER, Washington,...- Published at
- by manilatimes.net
neutralneutralCytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial- Published at
- by globenewswire.com
positivepositiveCytoDyn Announces Preliminary Findings in Study with SMC Laboratories
VANCOUVER, Washington, Sept. 24, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (- Published at
- by globenewswire.com
neutralneutralSeptember 2024 Letter to Shareholders
VANCOUVER, Washington, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, It continues to be a transformative year for CytoDyn Inc. (“CytoDyn” or...- Published at
- by globenewswire.com
positivepositiveCytoDyn Engages Leading CRO For Phase II Inflammation Trial
VANCOUVER, Washington, Aug. 23, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing...- Published at
- by globenewswire.com
neutralneutralCytoDyn Announces Completion of FDA Meeting on Phase II Study of Leronlimab in Patients with Relapsed/Refractory Microsatellite Stable Colorectal Cancer
VANCOUVER, Washington, Aug. 12, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (- Published at
- by globenewswire.com
mixedmixedBacterial Vaginosis Market to Register Incremental Growth During the Study Period (2020–2034) | DelveInsight
The current therapeutic landscape of bacterial vaginosis is driven by approved therapies such as XACIATO, SOLOSEC, and VivaGel. The launch of novel...- Published at
- by globenewswire.com
mixedmixedGlobal Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sci
The surge in liver disease therapeutics demand stems mainly from a growing population afflicted with liver ailments, elevated alcohol intake, and unhealthy...- Published at
- by globenewswire.com
mixedmixedCytomegalovirus Infections Market to Exhibit Moderate Growth by 2032, Evaluates DelveInsight | Leading Companies - ModernaTX, Inc., Merck Sharp & Dohme LLC, GlaxoSmithKline, AlloVir
The cytomegalovirus infections market size is expected to grow during the forecast period owing to the expected launch of novel emerging therapies for...- Published at
- by globenewswire.com
mixedmixedCytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
VANCOUVER, Washington, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (- Published at
- by globenewswire.com
mixedmixedHIV Type-1 Market is Likely to Increase at a Steady Growth Rate by 2032, Estimates DelveInsight | Key Companies Developing Therapies - ViiV Healthcare, GlaxoSmithKline, PPD, Merck, Gilead, Janssen, Ab
The HIV type-1 market is expected to grow by factors like an increase in the patient pool, rising healthcare spending across the globe, the expected entry...- Published at
- by prnewswire.com
mixedmixedLiver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight
/PRNewswire/ -- DelveInsight's Liver Cirrhosis Market Insights report includes a comprehensive understanding of current treatment practices, liver cirrhosis...- Published at
- by valuewalk.com
mixedmixed- Published at
- by benzinga.com
mixedmixedTrading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December
On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate had jumped 25 basis points, 50 basis points and then 75 points four times in a row in between each Federal Reserve meeting.ZURVYZFSVFTCNWFTCNNFROGN.MXROG.SWRO.SWRHHVFRHHBYRHHBFPVCTNWBOLTUMLIACFLI.VIFXN.MXIFX.DEIFNNYIFNNFHNK1.DEHINKFHEINYHEIAN.MXHEIA.PRHEIA.ASGTII.CNGTBIFGBTCETHEDTEN.MXDTEL.BRDTEGYDTEGFDTEA.DEDTE.PRDTE.MIDTE.DECYDYCSVICLNVBYZNBNPQYBNPQFAERGADSN.MXADS.MIADS.DEADDYYADDDF0TDF.L0QQ6.L0JVB.LOTCMNLSTGTIIFMCKLFMCCIFMCCCRTDWCRTD0K6M.L- Published at
- by globenewswire.com
neutralneutralDelveInsight Evaluates a Robust Nonalcoholic Fatty Liver Disease Pipeline as 110+ Influential Pharma Players to Set Foot in the Domain
Nonalcoholic fatty liver disease (NAFLD) is speedily becoming the most common cause of chronic liver disease, liver cirrhosis, hepatic decompensation,...